Young, J; Scherrer, A U; Günthard, Hf; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, Ca; Cavassini, M; Bernasconi, E; Vernazza, P; Hirschel, B; Battegay, M; Bucher, Hc; Swiss HIV Cohort Study, (2011). Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV medicine, 12(5), pp. 299-307. Oxford: Blackwell Science 10.1111/j.1468-1293.2010.00885.x
Full text not available from this repository.Darunavir was designed for activity against HIV resistant to other protease inhibitors (PIs). We assessed the efficacy, tolerability and risk factors for virological failure of darunavir for treatment-experienced patients seen in clinical practice.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology |
UniBE Contributor: |
Fux, Christoph Andreas |
ISSN: |
1464-2662 |
Publisher: |
Blackwell Science |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:13 |
Last Modified: |
05 Dec 2022 14:02 |
Publisher DOI: |
10.1111/j.1468-1293.2010.00885.x |
PubMed ID: |
20955357 |
Web of Science ID: |
000289113400005 |
URI: |
https://boris.unibe.ch/id/eprint/2711 (FactScience: 205579) |
Actions (login required)
 |
Edit item |